Advertisement

Chemicals and the Unborn

  • Philip C. Burcham
Chapter

Abstract

The thalidomide epidemic dispelled the complacent belief that the placenta is an impenetrable barrier protecting the foetus against all toxicants within a mother’s blood. In subsequent decades, knowledge of the risks accompanying exposure to developmental toxicants increased substantially. According to long-standing observations, substances that harm the unborn typically produce a combination of three toxic outcomes, namely, growth retardation, embryolethality and congenital abnormalities. Study of affected offspring revealed the influence of the precise timing of toxicant administration, with ‘windows of prenatal susceptibility’ identified for many developmental toxicants. While knowledge of the molecular basis for prenatal toxicity in animals has advanced significantly, extending these findings to humans is rarely straightforward. This chapter explores basic principles that apply during study of chemically induced birth defects, with particular focus on the mechanisms underlying the prenatal toxicity of drugs such as thalidomide and valproate as well as workplace toxicants such as cadmium and organic solvents.

Keywords

Embryolethality Teratogenicity Growth retardation Epigenetic teratogens Cadherins Teratogenicity testing Thalidomide Cadmium Toluene Bisphenol A Endocrine disruptors 

Going Further

  1. Bowen SE. Two serious and challenging medical complications associated with volatile substance misuse: sudden sniffing death and fetal solvent syndrome. Subst Use Misuse. 2011;46 Suppl 1:68–72.PubMedCrossRefGoogle Scholar
  2. Carney EW et al. Critical evaluation of current developmental toxicity testing strategies: a case of babies and their bathwater. Birth Defects Res B Dev Reprod Toxicol. 2011;92:395–403.PubMedCrossRefGoogle Scholar
  3. Chandler KJ et al. Evaluation of 309 environmental chemicals using a mouse embryonic stem cell adherent cell differentiation and cytotoxicity assay. PLoS One. 2011;6(6):e18540. doi: 10.1371/journal.pone.0018540. Epub 2011 Jun 7.PubMedCrossRefGoogle Scholar
  4. Christian MS. Test methods for assessing female reproductive and developmental toxicology. Chapter 29. In: Hayes WA, editor. Principles & methods of toxicology. 4th ed. Philadelphia: Taylor & Francis; 2001.Google Scholar
  5. D’Amato RJ et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082–5.PubMedCrossRefGoogle Scholar
  6. Duanmu Z et al. Developmental expression of aryl, estrogen, and hydroxysteroid sulfotransferases in pre-and postnatal human liver. J Pharmacol Exp Ther. 2006;316:1310–7.PubMedCrossRefGoogle Scholar
  7. Gupta RC. Reproductive and developmental toxicology. Burlington: Elsevier Science; 2011.Google Scholar
  8. Hannigan JH, Bowen SE. Reproductive toxicology and teratology of abused toluene. Syst Biol Reprod Med. 2010;56:184–200.PubMedCrossRefGoogle Scholar
  9. Iqbal M et al. Placental drug transporters and their role in fetal protection. Placenta. 2012;33:137–42.PubMedCrossRefGoogle Scholar
  10. Ito T, Handa H. Deciphering the mystery of thalidomide teratogenicity. Congenit Anom (Kyoto). 2012;52:1–7.CrossRefGoogle Scholar
  11. Ito T et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345–50.PubMedCrossRefGoogle Scholar
  12. Jergil M et al. Short-time gene expression response to valproic acid and valproic acid analogs in mouse embryonic stem cells. Toxicol Sci. 2011;121:328–42.PubMedCrossRefGoogle Scholar
  13. Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011;122:1–6.PubMedCrossRefGoogle Scholar
  14. LeBaron MJ et al. Epigenetics and chemical safety assessment. Mutat Res. 2010;705:83–95.PubMedCrossRefGoogle Scholar
  15. Lutz I, Kloas W. Amphibians as a model to study endocrine disruptors: I. Environmental pollution and estrogen receptor binding. Sci Tot Environ. 1999;225:49–57.CrossRefGoogle Scholar
  16. Manikkam M et al. Dioxin (TCDD) induces epigenetic transgenerational inheritance of adult onset disease and sperm epimutations. PLoS One. 2012;7(9):e46249. doi: 10.1371/journal.pone.0046249. Epub 2012 Sep 26.PubMedCrossRefGoogle Scholar
  17. Meeker JD. Exposure to environmental endocrine disruptors and child development. Arch Pediatr Adolesc Med. 2012;166:952–8.PubMedCrossRefGoogle Scholar
  18. Menegola E et al. Inhibition of histone deacetylase as a new mechanism of teratogenesis. Birth Defects Res C Embryo Today. 2006;78:345–53.PubMedCrossRefGoogle Scholar
  19. Myllynen P et al. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opin Drug Metab Toxicol. 2009;5:1483–99.PubMedCrossRefGoogle Scholar
  20. National Toxicology Brief on Bisphenol A. Available at www.niehs.nih.gov/health/topics/agents/sya-bpa/#4 (September 2008).
  21. Neubert D et al. Drug-induced damage to the embryo or fetus (molecular and multilateral approach to prenatal toxicology). Curr Top Pathol. 1980;69:241–331.PubMedCrossRefGoogle Scholar
  22. Parman T et al. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Med. 1999;5:582–5.PubMedCrossRefGoogle Scholar
  23. Rauh VA et al. Brain anomalies in children exposed prenatally to a common organophosphate pesticide. Proc Natl Acad Sci USA. 2012;109:7871–6.PubMedCrossRefGoogle Scholar
  24. Schug TT et al. Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol. 2011;127:204–15.PubMedCrossRefGoogle Scholar
  25. Shenefelt RE. Morphogenesis of malformations in hamsters caused by retinoic acid: relation to dose and stage at treatment. Teratology. 1972;5:103–18.PubMedCrossRefGoogle Scholar
  26. Thompson J, Bannigan J. Cadmium: toxic effects on the reproductive system and the embryo. Reprod Toxicol. 2008;25:304–15.PubMedCrossRefGoogle Scholar
  27. Tyl RW. Commentary on the role of maternal toxicity on developmental toxicity. Birth Defects Res B Dev Reprod Toxicol. 2012;95:262–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Philip C. Burcham
    • 1
  1. 1.School of Medicine and PharmacologyThe University of Western AustraliaPerthAustralia

Personalised recommendations